Hers compounded semaglutide is a telehealth-prescribed, pharmacy-compounded GLP-1 preparation offered through the Hers platform operated by Hims and Hers Health. It is not the same as FDA-approved Ozempic or Wegovy; instead, it is prepared by a licensed compounding pharmacy under federal compounding rules, which means it does not carry individual FDA approval for safety, efficacy, or quality for each batch.
How Compounded Semaglutide Differs From Branded GLP-1 Drugs
Branded semaglutide products, including Ozempic for type 2 diabetes and Wegovy for chronic weight management, went through New Drug Application review at the FDA. That process establishes a specific formulation, dosing schedule, and manufacturing standard. Compounded semaglutide, in contrast, is made in a pharmacy in response to a prescription. It may contain different salts, buffers, or concentrations and may be prepared as a multi-dose vial rather than a pen.
The FDA regulates compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Traditional 503A pharmacies compound for individual prescriptions, while 503B outsourcing facilities must meet stricter current Good Manufacturing Practice standards and register with the FDA. Users who are evaluating Hers or any similar service should understand which type of pharmacy fills the prescription.
How the Hers Telehealth Workflow Generally Operates
Hers brands itself as a women’s health telehealth service. For GLP-1 weight-management services, the general flow starts with an online questionnaire covering medical history, current medications, weight, target goals, and sometimes a video or photo-based check. A licensed clinician reviews the file, asks clarifying questions if needed, and decides whether the user is an appropriate candidate for a prescription.
If a prescription is written, an affiliated pharmacy ships the medication, typically monthly, with usage instructions. Follow-up visits, messaging support, and dose adjustments are handled through the platform. Pricing, eligibility, available strengths, and exact pharmacy partners change over time and can vary by state, so the company’s current website and terms should be considered the authoritative source for specifics.
FDA Compounding Rules and the Shortage Context
When a drug is on the FDA’s official shortage list, 503A and 503B pharmacies may legally compound a version of it to help meet patient needs, provided they comply with the relevant rules. Semaglutide was on the FDA shortage list for much of 2022 to 2024, which allowed large-scale compounding to expand. The FDA updates this list regularly, and once a shortage is resolved, compounding for that drug becomes more restricted.
Users should understand that even legal compounding does not mean the compounded product is identical in potency or purity to a branded drug. The FDA human drug compounding page explains these nuances and has issued warnings about counterfeit semaglutide salts such as semaglutide sodium, which have never been evaluated for safety in humans. Any reputable compounder should be able to confirm that they are using semaglutide base, not a non-approved salt form.
Key Factors to Weigh
Because compounded products vary, consumers can use a structured checklist when evaluating Hers or a similar service. The table below outlines questions that an informed user might bring to a clinician or customer-service representative.
| Factor | Why it matters | Question to ask |
|---|---|---|
| Pharmacy type | 503B facilities follow stricter manufacturing rules than 503A | Is my prescription filled by a 503A or 503B pharmacy? |
| Active ingredient | Only semaglutide base has human safety data | Is the product compounded with semaglutide base, not a salt form? |
| Quality testing | Independent testing supports potency and sterility claims | Do you publish third-party lab results for each batch? |
| Clinical oversight | Follow-up is critical for GLP-1 side effects | How often will I speak with a clinician after starting? |
| Adverse-event pathway | Reporting channels support overall drug safety | How do I report side effects, and are they reported to MedWatch? |
Safety and Clinical Considerations
Semaglutide in any form can cause nausea, vomiting, constipation, or diarrhea, particularly in the early weeks. More serious but less common concerns reported in clinical trials of the branded product include pancreatitis, gallbladder disease, and thyroid C-cell tumors in rodent studies. The branded labels carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. These concerns apply to compounded versions as well.
Candidates considering any GLP-1 therapy should take time to understand the broader picture. Our prediabetes overview covers risk factors, and our treatment hub describes how medications typically fit alongside lifestyle changes. Existing primary-care or endocrinology relationships should not be abandoned when using a telehealth service.
Consumer Protection and Red Flags
Regulators including the FDA and state boards of pharmacy have warned about unlicensed sellers, counterfeit products, and unsafe compounding practices. Users should avoid products marketed without clinician involvement, products that arrive without labeling, and sellers who pressure for rapid dose escalation. Hers, as a publicly traded company’s subsidiary, is more visible than smaller operators, but the general consumer-protection questions still apply.
If something feels off — unexpected symptoms, unclear labeling, or difficulty reaching a clinician — users can contact their state board of pharmacy, report to the FDA MedWatch system, and seek an in-person medical evaluation.
The Bottom Line
Hers compounded semaglutide is a telehealth-prescribed, pharmacy-compounded GLP-1 preparation. It is not FDA-approved as a branded drug, which means each batch is not individually reviewed by the agency. That does not necessarily make it unsafe, but it places more responsibility on the user and clinician to ask questions about pharmacy type, ingredient source, testing, and follow-up. Anyone considering this path should discuss it with a licensed clinician who knows their full history before starting therapy.
Medical disclaimer: This article is for educational purposes only and does not endorse any specific product or service. It is not a substitute for advice from a qualified healthcare professional. Do not start, stop, or change any medication based on information in this article.
